323 related articles for article (PubMed ID: 33657448)
1. Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury.
Cattel F; Giordano S; Bertiond C; Lupia T; Corcione S; Scaldaferri M; Angelone L; De Rosa FG
Respir Physiol Neurobiol; 2021 Jun; 288():103645. PubMed ID: 33657448
[TBL] [Abstract][Full Text] [Related]
2. The Synthetic Surfactant CHF5633 Restores Lung Function and Lung Architecture in Severe Acute Respiratory Distress Syndrome in Adult Rabbits.
Mikolka P; Kosutova P; Kolomaznik M; Nemcova N; Hanusrichterova J; Curstedt T; Johansson J; Calkovska A
Lung; 2024 Jun; 202(3):299-315. PubMed ID: 38684519
[TBL] [Abstract][Full Text] [Related]
3. Exogenous pulmonary surfactant in COVID-19 ARDS. The similarities to neonatal RDS suggest a new scenario for an 'old' strategy.
Bhatt RM; Clark HW; Girardis M; Busani S
BMJ Open Respir Res; 2021 Sep; 8(1):. PubMed ID: 34521648
[TBL] [Abstract][Full Text] [Related]
4. Surfactant therapy for acute lung injury and acute respiratory distress syndrome.
Raghavendran K; Willson D; Notter RH
Crit Care Clin; 2011 Jul; 27(3):525-59. PubMed ID: 21742216
[TBL] [Abstract][Full Text] [Related]
5. Pathomechanisms Underlying Hypoxemia in Two COVID-19-Associated Acute Respiratory Distress Syndrome Phenotypes: Insights From Thrombosis and Hemostasis.
Gando S; Wada T
Shock; 2022 Jan; 57(1):1-6. PubMed ID: 34172612
[TBL] [Abstract][Full Text] [Related]
6. Clinical review: Exogenous surfactant therapy for acute lung injury/acute respiratory distress syndrome--where do we go from here?
Dushianthan A; Cusack R; Goss V; Postle AD; Grocott MP
Crit Care; 2012 Nov; 16(6):238. PubMed ID: 23171712
[TBL] [Abstract][Full Text] [Related]
7. Surfactant replacement therapy as promising treatment for COVID-19: an updated narrative review.
Khudadah K; Ramadan A; Othman A; Refaey N; Elrosasy A; Rezkallah A; Heseba T; Moawad MHED; Mektebi A; Elejla SA; Abouzid M; Abdelazeem B
Biosci Rep; 2023 Aug; 43(8):. PubMed ID: 37497603
[TBL] [Abstract][Full Text] [Related]
8. Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study.
Piva S; DiBlasi RM; Slee AE; Jobe AH; Roccaro AM; Filippini M; Latronico N; Bertoni M; Marshall JC; Portman MA
Respir Res; 2021 Jan; 22(1):20. PubMed ID: 33461535
[TBL] [Abstract][Full Text] [Related]
9. Impact of synthetic surfactant CHF5633 with SP-B and SP-C analogues on lung function and inflammation in rabbit model of acute respiratory distress syndrome.
Mikolka P; Curstedt T; Feinstein R; Larsson A; Grendar M; Rising A; Johansson J
Physiol Rep; 2021 Jan; 9(1):e14700. PubMed ID: 33403805
[TBL] [Abstract][Full Text] [Related]
10. Rapid Phospholipid Turnover after Surfactant Nebulization in Severe COVID-19 Infection: A Randomized Clinical Trial.
Postle AD; Clark HW; Fink J; Madsen J; Koster G; Panchal M; Djukanovic R; Brealey D; Grocott MPW; Dushianthan A
Am J Respir Crit Care Med; 2022 Feb; 205(4):471-473. PubMed ID: 34874818
[No Abstract] [Full Text] [Related]
11. Pulmonary surfactant itself must be a strong defender against SARS-CoV-2.
Takano H
Med Hypotheses; 2020 Nov; 144():110020. PubMed ID: 32590326
[TBL] [Abstract][Full Text] [Related]
12. Surfactant alteration and replacement in acute respiratory distress syndrome.
Günther A; Ruppert C; Schmidt R; Markart P; Grimminger F; Walmrath D; Seeger W
Respir Res; 2001; 2(6):353-64. PubMed ID: 11737935
[TBL] [Abstract][Full Text] [Related]
13. Alveolar type II cells and pulmonary surfactant in COVID-19 era.
Calkovska A; Kolomaznik M; Calkovsky V
Physiol Res; 2021 Dec; 70(S2):S195-S208. PubMed ID: 34913352
[TBL] [Abstract][Full Text] [Related]
14. Severe COVID-19 ARDS Treated by Bronchoalveolar Lavage with Diluted Exogenous Pulmonary Surfactant as Salvage Therapy: In Pursuit of the Holy Grail?
Ruaro B; Confalonieri P; Pozzan R; Tavano S; Mondini L; Baratella E; Pagnin A; Lerda S; Geri P; Biolo M; Confalonieri M; Salton F
J Clin Med; 2022 Jun; 11(13):. PubMed ID: 35806862
[TBL] [Abstract][Full Text] [Related]
15. Surfactant for the Treatment of ARDS in a Patient With COVID-19.
Heching M; Lev S; Shitenberg D; Dicker D; Kramer MR
Chest; 2021 Jul; 160(1):e9-e12. PubMed ID: 33493441
[TBL] [Abstract][Full Text] [Related]
16. Effects of inhaled nitric oxide in COVID-19-induced ARDS - Is it worthwhile?
Lotz C; Muellenbach RM; Meybohm P; Mutlak H; Lepper PM; Rolfes CB; Peivandi A; Stumpner J; Kredel M; Kranke P; Torje I; Reyher C
Acta Anaesthesiol Scand; 2021 May; 65(5):629-632. PubMed ID: 33296498
[TBL] [Abstract][Full Text] [Related]
17. Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial.
Muller M; Lefebvre F; Harlay ML; Glady L; Becker G; Muller C; Aberkane O; Tawk M; Julians M; Romoli A; Hecketsweiler S; Schneider F; Pottecher J; Chamaraux-Tran TN
Trials; 2021 Feb; 22(1):131. PubMed ID: 33573681
[TBL] [Abstract][Full Text] [Related]
18. Lung Surfactant Protein B Peptide Mimics Interact with the Human ACE2 Receptor.
Waring AJ; Jung GC; Sharma SK; Walther FJ
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446012
[TBL] [Abstract][Full Text] [Related]
19. Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome.
Avdeev SN; Trushenko NV; Chikina SY; Tsareva NA; Merzhoeva ZM; Yaroshetskiy AI; Sopova VI; Sopova MI; Rosenberg OA; Schermuly RT; Kosanovic D
Respir Med; 2021; 185():106489. PubMed ID: 34087610
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of surfactant therapy of ARDS induced by hydrochloric acid aspiration followed by ventilator-induced lung injury - an animal study.
Mikolka P; Kosutova P; Kolomaznik M; Mateffy S; Nemcova N; Mokra D; Calkovska A
Physiol Res; 2022 Dec; 71(S2):S237-S249. PubMed ID: 36647912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
